- Home
- NVNI vs NERV Comparison
NVNI vs NERV Comparison
Compare NVNI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- NERV
- Stock Information
- Founded
- NVNI 2019
- NERV 2007
- Country
- NVNI Brazil
- NERV United States
- Employees
- NVNI N/A
- NERV N/A
- Industry
- NVNI
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- NERV Health Care
- Exchange
- NVNI Nasdaq
- NERV Nasdaq
- Market Cap
- NVNI 10.4M
- NERV 10.3M
- IPO Year
- NVNI N/A
- NERV 2014
- Fundamental
- Price
- NVNI $0.16
- NERV $1.76
- Analyst Decision
- NVNI
- NERV Hold
- Analyst Count
- NVNI 0
- NERV 1
- Target Price
- NVNI N/A
- NERV $5.00
- AVG Volume (30 Days)
- NVNI 3.6M
- NERV 18.7K
- Earning Date
- NVNI 05-07-2025
- NERV 05-05-2025
- Dividend Yield
- NVNI N/A
- NERV N/A
- EPS Growth
- NVNI N/A
- NERV N/A
- EPS
- NVNI N/A
- NERV 0.19
- Revenue
- NVNI $23,558,620.00
- NERV N/A
- Revenue This Year
- NVNI $25.91
- NERV N/A
- Revenue Next Year
- NVNI $21.68
- NERV N/A
- P/E Ratio
- NVNI N/A
- NERV $9.21
- Revenue Growth
- NVNI 38.59
- NERV N/A
- 52 Week Low
- NVNI $0.16
- NERV $1.15
- 52 Week High
- NVNI $12.19
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- NVNI 30.09
- NERV 58.11
- Support Level
- NVNI $0.16
- NERV $1.66
- Resistance Level
- NVNI $0.17
- NERV $1.81
- Average True Range (ATR)
- NVNI 0.02
- NERV 0.16
- MACD
- NVNI 0.06
- NERV 0.04
- Stochastic Oscillator
- NVNI 30.49
- NERV 92.42
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.